Author Archive: Tracy Cooley

Tracy Cooley

Tracy serves as the Director of Events Communications and handles all communications for BIO’s events and emerging company policy issues. She loves blogging and podcasting on all things biotech and believes in the great potential of the industry, looking for every opportunity to spread the message far and wide. Nearly everyone in her family is a golfer, and as such, she has what many people have called a “natural” swing. Sometimes she even hits the ball. Tracy just finished her ninth marathon, and has nearly mastered the skill of one-foot-in-front-of-the-other (usually, sometimes the laces get in the way). The joy of her life is her five-year-old daughter Josephine.

Latest Posts

Forbes on Flu

Forbes’ Jonathan Fahey wrote an excellent article on influenza and the H1N1 virus this morning. The article is significant for a couple reasons. First, he captures the overall situation so just in case you haven’t read a story or heard about H1N1 yet (and have been living under a rock), you get the full picture quickly and succinctly. Even if you have read about it, it’s always nice to get a quick recap just to Read More >

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: ,

Trubion Collaboration with Facet Biotech

Trubion Pharmaceuticals, Inc. (Nasdaq: TRBN) and Facet Biotech Corporation (Nasdaq: FACT) recently announced an agreement for the joint development and commercialization of TRU-016, a product candidate in phase 1 clinical development for chronic lymphocytic leukemia. TRU-016 is a CD37-directed Small Modular ImmunoPharmaceutical (SMIP(TM)) protein therapeutic. The collaboration agreement includes TRU-016 in all indications and all other CD37-directed protein therapeutics.

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: ,

Complete Genomics Sequences 14 Human Genomes

Complete Genomics Inc. announced that 14 human genomes now have been sequenced, analyzed and delivered to customers since March 2009. The company’s human genome sequencing technology helps to further research for cancer, metabolic and neurological diseases. Customers include academic research institutions and biopharmaceutical companies that are conducting disease studies to investigate conditions as diverse as cancer (breast, lung, colorectal and melanoma), HIV and schizophrenia. Complete Genomics Inc. will be presenting at the 8th Annual BIO Read More >

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: ,

Race to Develop H1N1 Vaccine

Execs from Inovio Biomedical Corporation and Novavax will be speaking at BIF about their experience in the race to develop a vaccine for H1N1. Below are a couple recent developments from these companies: Novavax Inc (NVAX.O) recently reported that its seasonal flu vaccine candidate, which uses virus-like particles, induced an immune response against H3N2, H1N1 and B and was well-tolerated in a mid-stage trial. Read the release. Inovio Biomedical Corp. (INO) said it will team up Read More >

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

PTC Therapeutics Announces Collaboration with Roche

PTC Therapeutics, Inc. announced a research collaboration and licensing agreement with Roche for development of orally bioavailable small molecules using PTC’s technology, Gene Expression Modulation by Small-molecules (GEMS™). As part of the collaboration, Roche is paying PTC Therapeutics $12 million as part of an agreement to develop small molecule CNS disease drugs. Subject to meeting milestones, there is the potential for PTC to earn up to $239 million in research, development, regulatory and commercial milestone Read More >

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: , , , , , ,